Download the presentation here: PDF
Download the presentation here: PDF Download the presentation here: PDF
Tapentadol: Next Generation Ultram 46 • Better Efficacy • Better Side Effect Profile • But, Scheduled. Product label So why the modest forecast estimates? © Defined Health, 2009 Pain Insight Briefing
Opioid Abuse Deterrence 47 © Defined Health, 2009 Pain Insight Briefing
- Page 1 and 2: Game Changing Plays in the Pain Mar
- Page 3 and 4: Our Disclaimer 3 The information in
- Page 5 and 6: Everyone Hurts “Pain is whatever
- Page 7 and 8: It’s A Big Market with a Few Domi
- Page 9 and 10: $ Millions But Few “Big Pharma-Si
- Page 11 and 12: Pain Historically: Drug Delivery ha
- Page 13 and 14: It’s Getting Tougher Labopharm La
- Page 15 and 16: The Risk : Reward Profile for Novel
- Page 17 and 18: Current Standard of Care for Pain
- Page 19 and 20: Leaving Plenty of Unmet Need to Be
- Page 21 and 22: In the Meantime, Let’s Teach Old
- Page 23 and 24: A Better NSAID: NicOx • Naproxcin
- Page 25 and 26: A Better NSAID: NicOx 25 Company pr
- Page 27 and 28: A Better NSAID: Pozen / AstraZeneca
- Page 29 and 30: The First-to-Market Topical NSAIDs
- Page 31 and 32: Even So, Flector is Expected To Be
- Page 33 and 34: Now We Have a Patch and a Gel Volta
- Page 35 and 36: The Need is Clear 35 © Defined Hea
- Page 37 and 38: Progenics / Wyeth: Making Opioids M
- Page 39 and 40: Adolor / Pfizer: Making Opioids Mor
- Page 41 and 42: Like All Things CNS, It’s Not So
- Page 43 and 44: A New, and Better Opioid from J&J /
- Page 45: A New, and Better Opioid from J&J /
- Page 49 and 50: King Pharmaceuticals: Making Big Be
- Page 51 and 52: But Also Significant Hurdles • Te
- Page 53 and 54: The Technologies are Not the Proble
- Page 55 and 56: The Real Issue is Risk Management
- Page 57 and 58: Fentanyl: Again, REMS is the Big Re
- Page 59 and 60: Lessons from Fentora 59 What the FD
- Page 61 and 62: For Some Mechanisms, the US Regulat
- Page 63 and 64: FAAH Pipeline 63 Compound SSR 10101
- Page 65 and 66: FAAH Pipeline KDS-4103, acquired by
- Page 67 and 68: Addressing the Big Problem 67 >50%
- Page 69 and 70: New MOA Challenges 69 NeuroDiscover
- Page 71 and 72: New MOA Challenges 71 The identific
- Page 73 and 74: TRPV1 • The transient receptor po
- Page 75 and 76: TRPV1: Target for Novel Analgesics
- Page 77 and 78: TRPV1 Antagonists: Hot … Too Hot
- Page 79 and 80: TRPV1 Antagonist Pipeline Compound
- Page 81 and 82: TRPV1 Antagonist Pipeline 81 Compou
- Page 83 and 84: TRPV3: Hopeful, But Too Early to Te
- Page 85 and 86: Good Phase III Data, An Accepted ND
- Page 87 and 88: Pfizer Pursuing Multiple Chronic Pa
- Page 89 and 90: Concerning, but Transient Adverse E
- Page 91 and 92: Will NGF for Pain Be Like TNF is fo
- Page 93 and 94: Repurposed anti-TNF Antibodies for
- Page 95 and 96: What’s Next for Pain? • Continu
Tapentadol: Next Generation Ultram<br />
46<br />
• Better Efficacy<br />
• Better Side Effect Profile<br />
• But, Scheduled.<br />
Product label<br />
So why <strong>the</strong> modest forecast estimates?<br />
© Defined Health, 2009<br />
Pain Insight Briefing